Xu T, Wang K, Chen Y, Yu Y, et al. Adjuvant bacillus Calmette-Guerin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study. Int Immunopharmacol 2026;172:116186.
PMID: 41548434